K29.3 – Chronic Superficial Gastritis
K29.3 is the ICD-10 code for chronic superficial gastritis, a long-lasting inflammation of the stomach lining causing upper abdominal pain, bloating, and nausea.
Things worth knowing about "K29.3"
K29.3 is the ICD-10 code for chronic superficial gastritis, a long-lasting inflammation of the stomach lining causing upper abdominal pain, bloating, and nausea.
What is K29.3?
The ICD-10 code K29.3 stands for chronic superficial gastritis, a persistent inflammation of the stomach lining (gastric mucosa) that is limited to the uppermost epithelial layer. It is one of the most commonly diagnosed stomach conditions worldwide and falls under category K29 (Gastritis and duodenitis) in the International Classification of Diseases (ICD-10).
Causes
Chronic superficial gastritis can be triggered by several factors:
- Helicobacter pylori: This bacterium is the most frequent cause. It colonises the gastric mucosa and induces a chronic inflammatory response.
- Medications: Regular use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen or aspirin can damage the stomach lining.
- Alcohol and smoking: Chronic consumption of alcohol and tobacco causes persistent irritation of the gastric mucosa.
- Stress: Prolonged physical or psychological stress can contribute to the onset or worsening of the condition.
- Dietary habits: Irregular meals, highly spiced or fatty foods, and poor nutrition can strain the stomach lining.
- Autoimmune processes: In rarer cases, an autoimmune reaction targets the gastric mucosa (Type A gastritis).
Symptoms
Symptoms of K29.3 can vary widely. Common complaints include:
- Dull or burning upper abdominal pain, often occurring shortly after eating
- Nausea and occasional vomiting
- Bloating and a feeling of pressure in the upper abdomen
- Heartburn and acid reflux
- Loss of appetite and early satiety
In some cases, chronic superficial gastritis is completely asymptomatic and is discovered incidentally during an examination for another condition.
Diagnosis
Diagnosis of chronic superficial gastritis (K29.3) is typically established through the following approaches:
- Gastroscopy (upper endoscopy): Direct visualisation of the stomach lining using an endoscope is the most reliable method. Redness, swelling, or mucosal changes can be identified.
- Biopsy: Tissue samples from the gastric mucosa are taken and examined microscopically to assess the extent of inflammation and identify potential pathogens.
- Helicobacter pylori testing: The bacterium can be detected via breath test, stool antigen test, or biopsy-based testing.
- Blood tests: Used to assess inflammatory markers or detect autoantibodies.
Treatment
Treatment is guided by the underlying cause and severity of the condition:
Pharmacological Therapy
- Proton pump inhibitors (PPIs) such as omeprazole or pantoprazole reduce gastric acid production and support mucosal healing.
- If Helicobacter pylori is confirmed: eradication therapy using a combination of antibiotics (e.g., clarithromycin, amoxicillin) and a PPI, known as triple therapy.
- Antacids may be used short-term for symptom relief from heartburn.
General Measures
- Discontinuation or reduction of mucosal-damaging medications (NSAIDs), in consultation with a doctor
- Avoidance of alcohol and tobacco
- Regular, easily digestible meals; avoiding very fatty, spicy, or acidic foods
- Stress reduction through relaxation techniques such as yoga or meditation
Prognosis
Chronic superficial gastritis (K29.3) generally responds well to consistent treatment. When the underlying cause – such as Helicobacter pylori infection – is successfully addressed, complete healing often follows. Without treatment, however, the condition may progress to more severe forms of gastritis or other gastric disorders. Regular follow-up examinations are recommended.
References
- Madisch A. et al.: Leitlinie Gastritis – Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), 2021.
- World Health Organization (WHO): ICD-10 Version 2019 – K29 Gastritis and duodenitis. Geneva: WHO, 2019.
- Malfertheiner P. et al.: Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut, 2017; 66(1):6–30.
Building Blocks for a Healthy Life
As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.
Verwandte Produkte
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For Healthy Oral Flora & Dental Care
Formulated lozenges with Dentalac®, lactic acid bacteria, and Lactoferrin CLN®
For your universal protection
As one of the most valuable proteins in the body, lactoferrin is a natural component of the immune system.
For your iron balance
Specially formulated for your iron balance with plant-based curry leaf iron, Lactoferrin CLN®, and natural Vitamin C from rose hips.